WALTHAM, Mass.--(BUSINESS WIRE)--Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for its fiscal fourth quarter and full fiscal year ended December 31, 2011.
“We continued to develop our business in 2011. Our genetic testing revenue has grown by more than forty percent this year over last year as we added new partnerships for distribution of our tests. In addition, our collaboration with Stanford University continued with an extension study whose results showed that the genetic patterns identified by our Weight Management Test can help individuals lose more weight when diets are selected based on genotype,” said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. “Most importantly, we have advanced our large, clinical program with our partners the University of Michigan and Renaissance Health and completed enrollment of over 5,400 patients in a landmark pivotal study. Positive results from the study would set the PST®Genetic Test as a key determinant of periodontal disease risk. This study has the potential to create new insurance benefit programs for insurers and lead to reimbursement for the test.”